Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Alexion Pharm Inc (ALXN)

Alexion Pharm Inc (ALXN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 40,335,968
  • Shares Outstanding, K 221,019
  • Annual Sales, $ 6,070 M
  • Annual Income, $ 603,400 K
  • 60-Month Beta 1.25
  • Price/Sales 6.53
  • Price/Cash Flow 8.00
  • Price/Book 3.24
Trade ALXN with:
  • Price/Earnings ttm 15.07
  • Earnings Per Share ttm 11.91
  • Most Recent Earnings 3.52 on 04/30/21
  • Next Earnings Date 07/29/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview

Details
  • Implied Volatility 0.00%
  • Historical Volatility 15.78%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate 3.22
  • Number of Estimates 4
  • High Estimate 3.63
  • Low Estimate 2.89
  • Prior Year 2.87
  • Growth Rate Est. (year over year) +12.20%

Price Performance

See More
Period Period Low Period High Performance
1-Month
178.51 +2.24%
on 07/19/21
187.45 -2.64%
on 07/14/21
+1.81 (+1.00%)
since 06/18/21
3-Month
164.83 +10.72%
on 04/29/21
187.45 -2.64%
on 07/14/21
+15.96 (+9.58%)
since 04/20/21
52-Week
99.91 +82.66%
on 08/21/20
187.45 -2.64%
on 07/14/21
+72.96 (+66.61%)
since 07/20/20

Most Recent Stories

More News
Wilson Disease Drugs Market: Trends, Key Players, Overview, Competitive Breakdown and Regional Forecast by 2029

Research Nester has released a report titled "" which delivers detailed overview of the global Wilson disease drugs market in terms of market segmentation by indication, drug type, end-user and by region....

MRK : 71.93 (+0.35%)
BHC : 26.11 (-4.25%)
ALXN : 182.50 (+1.70%)
KDMN : 8.76 (+0.34%)
TEVA : 8.69 (-3.34%)
Global $15.25 Bn Enzymes Markets, 2015-2020, 2020-2025F, 2030F: Asparginase, Lipase, Protease, Nattokinase, Chitinase, Serratiopeptidase, Collagenase, Ligase

/PRNewswire/ -- The report has been added to offering.

ABBV : 106.40 (-1.23%)
ALXN : 182.50 (+1.70%)
AGN : 193.02 (+0.02%)
HZNP : 108.02 (-1.54%)
PFE : 44.20 (+0.71%)
iCo Therapeutics Inc. Announces Shareholder Approval of Business Combination with Satellos Bioscience Inc.

Vancouver, British Columbia--(Newsfile Corp. - August 5, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company") is pleased to announce that at an annual and special meeting of...

ALXN : 182.50 (+1.70%)
ICO.VN : 0.105 (unch)
ICOTF : 1.0679 (+1.70%)
ALXN vs. TECH: Which Stock Is the Better Value Option?

ALXN vs. TECH: Which Stock Is the Better Value Option?

ALXN : 182.50 (+1.70%)
TECH : 528.82 (-1.03%)
AbbVie (ABBV) Venclexta Gets Breakthrough Therapy Tag for MDS

The FDA grants a Breakthrough Therapy designation to AbbVie's (ABBV) Venclexta in combination with azacitidine for treating adult patients with higher risk myelodysplastic syndrome.

RHHBY : 45.5700 (-1.09%)
JNJ : 163.81 (-0.57%)
ALXN : 182.50 (+1.70%)
ABBV : 106.40 (-1.23%)
Bayer's (BAYRY) Parkinson's Disease Therapy Gets Fast Track Tag

The FDA grants a Fast Track status to Bayer's (BAYRY) DA01 cell therapy which is being developed for the treatment of Parkinson's disease.

RHHBY : 45.5700 (-1.09%)
ALXN : 182.50 (+1.70%)
BAYRY : 13.2450 (-0.34%)
RGEN : 306.05 (-0.28%)
Moderna Soars on Inclusion to S&P 500: ETFs in Focus

Moderna, known for its success in the COVID-19 vaccine, has entered the big league with its addition to the S&P 500 Index.

ALXN : 182.50 (+1.70%)
IBB : 169.91 (-2.13%)
BBH : 213.73 (-1.92%)
GERM : 42.89 (-2.96%)
IBBQ : 26.55 (-2.32%)
Alexion (ALXN) Reports Positive Data on Ultomiris From gMG Study

Alexion (ALXN) announces that the phase III study of Ultomiris for the indication of gMG met its primary goal.

AZN : 58.50 (+5.29%)
ALXN : 182.50 (+1.70%)
RGEN : 306.05 (-0.28%)
ZTS : 198.62 (+0.07%)
Is a Beat in the Cards for Anthem (ANTM) in Q2 Earnings?

Anthem's (ANTM) second-quarter results are likely to benefit on the back of higher premiums coupled with growing Medicaid and Medicare membership, partly offset by escalating costs.

ALXN : 182.50 (+1.70%)
HUM : 404.11 (-0.90%)
MOH : 277.39 (-0.27%)
ANTM : 376.90 (-0.69%)
Moderna (MRNA) Set to Join S&P 500 Riding on Vaccine Success

Moderna's (MRNA) success with its COVID-19 vaccine, mRNA-1273, continues to drive the stock. The company crosses $100-billion in market capitalization and will join the S&P 500 soon.

AZN : 58.50 (+5.29%)
PFE : 44.20 (+0.71%)
ALXN : 182.50 (+1.70%)
MRNA : 423.33 (-1.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. Alexion is the global leader in complement inhibition and has developed and commercializes...

See More

Key Turning Points

3rd Resistance Point 185.94
2nd Resistance Point 184.31
1st Resistance Point 183.40
Last Price 182.50
1st Support Level 180.86
2nd Support Level 179.23
3rd Support Level 178.32

See More

52-Week High 187.45
Last Price 182.50
Fibonacci 61.8% 154.01
Fibonacci 50% 143.68
Fibonacci 38.2% 133.35
52-Week Low 99.91

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar